Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. READ MORE. Furthermore, copies of the offer document and the amendment of the offer are also available free of charge by contacting D.F. DGAP-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the January 5, 2021, 10:00 AM EST SHARE THIS ARTICLE News Center / Press Releases / Press Release Illumina and QIAGEN Partner to Deliver Sequencing-Based In-Vitro Diagnostic (IVD) Tests Partnership to accelerate the adoption of next-generation sequencing (NGS) in clinical decision-making QIAGEN Secures Option to License Discoveries from TScan’s TCR/Target ID Platform for Use in Potential Diagnostics for COVID-19 WALTHAM, Mass.–(BUSINESS WIRE)– TScan Therapeutics, a biopharmaceutical company focused on the development of T-cell receptor (TCR)-engineered T cell therapies in oncology, today announced the signing of a research license and option agreement with QIAGEN … READ MORE. QIAGEN has successfully assessed its SARS-CoV-2 PCR tests against genetic mutations of the virus uploaded to the GISAID and GenBank public databases since May 2020. To the extent that any of the statements contained herein relating to QIAGEN's outlook, products, launches, pipeline, regulatory submissions, collaborations, markets, strategy, employees, taxes or operating results; QIAGEN’s plans to continue its growth strategy and the execution of its strategy; QIAGEN’s commitment to support the global response to the COVID-19 pandemic; QIAGEN’s ability to address molecular testing needs in the life sciences and molecular diagnostics; the magnitude and duration of the COVID-19 pandemic; QIAGEN’s ability to increase its value through its growth strategy and initiatives; QIAGEN’s commercial initiatives, including initiatives to support the global response to the COVID-19 pandemic, to strengthen its leadership in sample technologies, to further its leadership in tuberculosis detection, to accelerate commercialization of the QIAstat-Dx and NeuMoDx systems, and to enter the digital PCR market with the QIAcuity launch; impacts of the COVID-19 pandemic on QIAGEN’s business; and. In addition, Thermo Fisher’s tender offer statement and other documents filed with the SEC are available at https://ir.thermofisher.com/investors. Automation solutions tie these together in seamless and cost-effective workflows. READ MORE. Announces Conversion Price of New Net Share Settled Convertible Bonds and Price to Non-US Holders to Sell Outstanding Convertible Notes Due 2021 07.01.2021. New features in the QIAGEN OmicSoft 10.1.2 release 10.1.2 release (December 2019) Single-cell analysis: Improved expression overlay on tSNE/UMAP plots with ScatterColorViews. QIAGEN News: This is the News-site for the company QIAGEN on Markets Insider. Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 21.12.20 QIAGEN announces appointment of new Supervisory Board … This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any ordinary shares of QIAGEN or any other securities, nor is it a substitute for the tender offer materials that Thermo Fisher or its acquisition subsidiary file with the SEC and publish in Germany. In an ad-hoc press release, Qiagen announced that it will "suspend ongoing NGS-related instrument development activities" including its proprietary GeneReader NGS System, which will be supported for existing users, in order to "expanding its offering of universal NGS consumables solutions for use with any sequencer", particularly NGS market leader Illumina’s sequencing hardware. Due to the absence of accurate breakpoint data for most of these lesions, 3,348 entries have been mapped in this release. Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today confirmed that its offer to acquire all of QIAGEN's ordinary shares for an increased price of €43.00 per share in cash will expire at 24:00 hours (Frankfurt am Main local time) / 18:00 hours (New York local time) on Monday, August 10, 2020. QIAGEN CLC new release Check out some of the many new features delivered in the QIAGEN CLC solutions QIAGEN CLC Genomics Workbench 20.0: A host of new features help you scale your research, and allow you to ramp up your productivity by taking your multi-sample analyses to … News Release View printer-friendly version << Back: LabCorp Announces Availability of New QIAGEN therascreen FGFR mutation analysis companion diagnostic for Bladder Cancer. QIAGEN’s growth strategy is anchored on these commercial initiatives: QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Stay up-to-date with our latest … QIAGEN has successfully assessed its SARS-CoV-2 PCR tests against genetic mutations of the virus uploaded to the GISAID and GenBank public databases since May 2020. With respect to the acceptance of the tender offer outside Germany and the United States, no responsibility is assumed for the compliance with such legal requirements applicable in the respective jurisdiction. VENLO, The Netherlands--(BUSINESS WIRE)-- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that Dr. Toralf Haag has been appointed a member of the Supervisory Board with immediate effect.He will also become a member of the Audit Committee. Latest news on QIAGEN’s COVID-19 efforts. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any ordinary shares of QIAGEN or any other securities, nor is it a substitute for the tender offer materials that Thermo Fisher or its acquisition subsidiary file with the SEC and publish in Germany. “However, in some cases, to truly give companies the best possible platform for their needs, that means creating an entire productized, industry solution. We have dramatically scaled up production, moving to 24 hour, seven-day-a-week operations at our manufacturing sites. Latest press releases. Companies in the life sciences … We deliver Sample to Insight solutions for molecular testing, propelling our customers from start to finish to unlock new insights. INVESTORS AND SHAREHOLDERS OF QIAGEN ARE URGED TO READ THESE DOCUMENTS CAREFULLY BECAUSE THEY, AND NOT THIS DOCUMENT, GOVERN THE TERMS AND CONDITIONS OF THE TENDER OFFER, AND BECAUSE THEY CONTAIN IMPORTANT INFORMATION THAT SUCH PERSONS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR ORDINARY SHARES. QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 2021-01-19 / 22:02 QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). Download PDF 394.4 KB. “We respect the decision of our shareholders and will now continue to execute our strategy to deliver growth and create greater value with our Sample to Insight portfolio that addresses growing molecular testing needs in the life sciences and molecular diagnostics,” said Dr. HÃ¥kan, Björklund, Chairman of the Supervisory Board of QIAGEN N.V. “The magnitude and duration of the global coronavirus pandemic have proven the increasingly critical importance of molecular testing to society. The amended business combination agreement has been terminated due to the acceptance threshold not having been met. Additional Information and Where to Find It. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it will continue to execute its successful growth strategy aiming to create significant value for shareholders and other stakeholders after the voluntary public takeover offer by Thermo Fisher Scientific, Inc. (NYSE: TMO) did not achieve the minimum 66.67% acceptance threshold from QIAGEN shareholders. DGAP Post-admission Duties announcement: QIAGEN N.V. / Share Repurchase QIAGEN N.V.: Release of a capital market information 2020-12-22 / 10:31 Dissemination of a Post-admission Duties announcement transmitted by DGAP - a service of EQS Group AG. QIAGEN has filed a solicitation/recommendation statement on Schedule 14D-9 with the SEC with respect to the tender offer on May 18, 2020, as amended from time to time; in addition, QIAGEN has published a document combining the recommendation statement pursuant to Sec. Further information can be found at, Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. Get the latest Qiagen N.V. (QGEN) stock news and headlines to help you in your trading and investing decisions. As of June 30, 2020, QIAGEN employed more than 5,200 people in over 35 locations worldwide. In addition, on July 22, 2020, QIAGEN has published a supplement to the solicitation/recommendation statement, which QIAGEN filed with an amendment to its solicitation/recommendation statement on Schedule 14D-9 with the SEC. QIAGEN to continue successful growth strategy focused on execution and greater value creation after voluntary public takeover offer falls short. the proposed acquisition of NeuMoDx and the potential benefits of such acquisition; are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. The amended business combination agreement has been terminated due to the acceptance threshold not having been met. The amendment of the offer has been published in Germany and filed with the SEC in an amendment to the tender offer statement on Schedule TO on July 17, 2020. He will also become a member of the Audit Committee. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. 27 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz, “WpÜG”) and … Tuesday morning, Qiagen's stock dropped more than 20% on the news of Schatz's departure and the weak third quarter sales numbers. Dr. Haag was chosen as part of an expansion process launched by the Supervisory Board to further complement … QIAGEN to complement COVID-19 testing portfolio with novel QIAprep& kit that simplifies and accelerates PCR analysis for research applications. DGAP Voting Rights Announcement: QIAGEN N.V. QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of ... 08.01.21 - Businesswire Assay technologies make these biomolecules visible and ready for analysis. DGAP Voting Rights Announcement: QIAGEN N.V. QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 2020-12-30 / 22:04 Dissemination of a Voting Rights Announcement transmitted by DGAP - a … (PRESS RELEASE) VENLO, the Netherlands, 8-Jan-2021 — /EuropaWire/ — QIAGEN announces the appointment of Dr. Toralf Haag as a member of the Supervisory Board with immediate effect. By using this site you agree to the use of cookies for analytics, personalized content and ads. The terms and conditions of the tender offer are published in, and the offer to purchase ordinary shares of QIAGEN is made only pursuant to, the offer document as permitted for publication by the German Federal Financial Supervisory Authority (, THE TENDER OFFER MATERIALS (INCLUDING THE OFFER DOCUMENT, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS), THE SOLICITATION / RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 AND QIAGEN’S RECOMMENDATION STATEMENT PURSUANT TO SEC. As we focus on greater value creation, QIAGEN builds on a disciplined capital allocation policy anchored by a healthy balance sheet to support investments into our business along with a commitment to increasing returns to shareholders.”. QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 2021-01-08 / 22:05 QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 2021-01-05 / 16:00 QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that Dr. Toralf Haag has been appointed a member of the Supervisory Board with immediate effect. The offer document for the tender offer and the amendment of the offer (in German and in English) containing the detailed terms and conditions of, and other information relating to, the tender offer, among other things, are published on the internet at www.thermofisher.com. December 12, 2020 StreetInsider Press Release QIAGEN N.V. Our employees have demonstrated resilience and deep expertise in meeting the challenges of the pandemic, and will continue to play an essential role in building QIAGEN as a unique and differentiated leader in molecular testing through a commitment to execution on our goals.”, Roland Sackers, Chief Financial Officer of QIAGEN N.V., added: “QIAGEN is moving forward from a position of strength with robust growth prospects, anchored by a differentiated portfolio and multiple new product launches in the pipeline. QIAGEN has filed a solicitation/recommendation statement on Schedule 14D-9 with the SEC with respect to the tender offer on May 18, 2020, as amended from time to time; in addition, QIAGEN has published a document combining the recommendation statement pursuant to Sec. With disclosure dated November 11, 2020, QIAGEN N.V. announced pursuant to Article 5 Section (1) and (6) of the EU Regulation no 596/2014 and Article 2 Section (1) of the Delegated EU Regulation no … QIAGEN increases outlook for 2020 and 2021. SUBSCRIBE TO RSS-FEED. ... CEO of AODocs, said in a press release. The issuer is solely responsible for the content of this … He will also become a member of the Audit Committee. Dr. Haag was chosen as part of an expansion process launched by the … QIAGEN N.V. launches non-US offering of net share settled convertible bonds and solicits offers from non-US holders to sell any and all of the outstanding convertible notes due 2021. Generate tSNE or PCA plots using OmicSoft, or import coordinates from older analyses, then visualize gene expression intensity over the plots. The Fall 2020 Release of the Human Gene Mutation Database (HGMD) Professional is available, expanding the world’s largest collection of human inherited disease mutations to 298,409 entries–that’s 9,063 more than the previous release. Get the latest Qiagen N.V. (QGEN) stock news and headlines to help you in your trading and investing decisions. Investegate 40d. By using this site you agree to the use of cookies for analytics, personalized content and ads. 27 WPÜG AND POSITION STATEMENT (GEMOTIVEERDE STANDPUNTBEPALING) PURSUANT TO SECTION 18 AND APPENDIX G OF THE DUTCH DECREE ON PUBLIC TAKEOVERS (BESLUIT OPENBARE BIEDINGEN), AS THEY MAY BE AMENDED FROM TIME TO TIME, CONTAIN IMPORTANT INFORMATION. At QIAGEN we work tirelessly on novel approaches to support healthcare workers and scientists in their fight against COVID-19. Latest news on QIAGEN’s COVID-19 efforts. QIAGEN Announces Global Distribution Agreement for the COSMIC Database from the Wellcome Sanger Institute. QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 08.01.2021 / 22:05 Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG. The terms and conditions of the tender offer are published in, and the offer to purchase ordinary shares of QIAGEN is made only pursuant to, the offer document as permitted for publication by the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht) and related offer materials prepared by Thermo Fisher and its acquisition subsidiary, including the amendment of the offer. Stay up-to-date with our latest developments here. The announcement of the 15-year partnership of next generation sequencing (NGS) market leader Illumina and QIAGEN came after Illumina cut its 2019 guidance from 13-14% prior guidance and 13% consensus to 6% FY revenue growth after reporting a second-quarter revenue loss of approximately US$52m (US$835 million, lower … WALTHAM, Mass.– (BUSINESS WIRE)– TScan Therapeutics, a biopharmaceutical company focused on the development of T-cell receptor (TCR)-engineered T cell therapies in oncology, today announced the signing of a research license and option agreement with QIAGEN to develop T cell-based laboratory tests for detecting prior exposure to the novel coronavirus, SARS-CoV-2, using discoveries from TScan’s … PRESS RELEASE August 24, 2020 Dr. Haag was chosen as part of an … DGAP-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the … HGVS nomenclature is also provided for this dataset. On July 16, 2020, Thermo Fisher and QIAGEN … A total of 47% of the outstanding QIAGEN shares were tendered into the offer of EUR 43.00 per share at the expiry of the Acceptance Period on Monday, August 10, 2020, at Midnight Frankfurt time / 18:00 New York time. 27 WPÜG AND POSITION STATEMENT (. HGMD Professional 2020.3 Release. % of the outstanding QIAGEN shares were tendered into the offer of EUR 43.00 per share at the expiry of the Acceptance Period on Monday, August 10, 2020, at Midnight Frankfurt time / 18:00 New York time. 10.12.2020. DGAP Post-admission Duties announcement: QIAGEN N.V. / Share Repurchase QIAGEN N.V.: Release of a capital market information 24.11.2020 / 10:46 Dissemination of a Post-admission Duties announcement transmitted by DGAP - a service of EQS Group AG. QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 2021-01-19 / 22:02 The tender offer materials, including the offer document, the amendment of the offer and the related letter of transmittal and certain other tender offer documents, and the solicitation/recommendation statement, the supplemental solicitation/recommendation statement and other documents filed with the SEC by Thermo Fisher or QIAGEN, may be obtained free of charge at the SEC’s website at www.sec.gov or at QIAGEN’s website at www.qiagen.com or by contacting QIAGEN’s investor relations department at 240-686-2222 or at Thermo Fisher’s website at www.thermofisher.com or by contacting Thermo Fisher’s investor relations department at 781-622-1111. Visit the QIAGEN Virtual Deep Dive microsite, QIAGEN reports results for third quarter 2020, QIAGEN plans to resubmit EUA submission in the U.S. for QIAreach SARS CoV-2 Antigen Test in the first quarter of 2021, QIAGEN confirms effectiveness of its SARS-CoV-2 PCR tests in the face of mutations of the coronavirus, QIAGEN Announces Global Distribution Agreement for the COSMIC Database from the Wellcome Sanger Institute, QIAGEN announces appointment of new Supervisory Board member, QIAGEN launches portable digital SARS-CoV-2 antigen test that can accurately analyze over 30 samples per hour, QIAGEN announces start of share repurchase for up to $100 million, QIAGEN launches NeuMoDx multiplex test to complete range of SARS-CoV-2 testing solutions in Europe and other markets, QIAGEN collaborates with BioNTech on companion diagnostics development for HPV-associated squamous cell carcinoma of the head and neck, QIAGEN to launch QuantiFERON SARS-CoV-2 for research into causes, spread and control of COVID-19 through T-cell response, QIAGEN increases outlook for 2020 and 2021. 20.11.2020 QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | Qiagen N.V. | News | Nachricht | Mitteilung VENLO, The Netherlands--(BUSINESS WIRE)-- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that Dr. Toralf Haag has been appointed a member of the Supervisory Board with immediate effect.He will also become a member of the Audit Committee. Assay technologies make these biomolecules visible and ready for analysis. 08.12.2020. Bernard will be tasked with working with CFO Roland Sackers to lead the company through its new … QIAGEN N.V. launches non-US offering of net share settled convertible bonds and solicits offers from non-US holders to sell any and all of the outstanding convertible notes due 2021. Venlo, The Netherlands, August 13, 2020 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it will continue to execute its successful growth strategy aiming to create significant value for shareholders and other stakeholders after the voluntary public takeover offer by Thermo Fisher Scientific, Inc. (NYSE: TMO) did not achieve the minimum 66.67% acceptance threshold from QIAGEN shareholders. 27 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz, “WpÜG”) and the position statement (gemotiveerde standpuntbepaling) pursuant to Section 18 and appendix G of the Dutch Decree on Public Takeovers (Besluit Openbare Biedingen). A latest round of assessments conducted in January 2021 again confirmed that no recorded mutations affected the sensitivity of QIAGEN assays … QIAGEN N.V. : Release according to Article 40. QIAGEN’s business prospects have improved significantly, as shown in our performance for the first half of 2020 and the strong outlook for the rest of this year and for 2021,” said Thierry Bernard, Chief Executive Officer of QIAGEN N.V. “In light of the outcome, we will also move forward with our plans to fully acquire NeuMoDx, Inc., which is growing fast thanks to its unique offering of molecular diagnostic testing platforms along with a solution for coronavirus testing and an expanding range of assays in Europe, the U.S. and rest of the world. At QIAGEN we work tirelessly on novel approaches to support healthcare workers and scientists in their fight against COVID-19. Dec 08 … QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it plans to resubmit in the first quarter of 2021 its QIAreach SARS-CoV-2 Antigen Test to the U.S. Food and Drug Administration for Emergency Use Authorization to detect SARS-CoV-2 antigens in people with active infections in 15 … PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE. PetaGene, AstraZeneca, QIAGEN, and More: News From October 2019 October 31, 2019. ... QIAGEN N.V. : Release of a capital market information. New Test Further Underscores LabCorp’s Leadership in Development and Commercialization of Innovative Lab Testing. 08.01.2021. QIAGEN releases QIAstat-Dx test kit to the U.S. as first syndromic test for detection of SARS-CoV-2 coronavirus under new FDA policy A subset of the HGMD gross deletions has now been mapped to both builds of the reference genome (NCBI38/hg38 and legacy NCBI37/hg19). Acceptance of the tender offer by shareholders that are resident outside Germany and the United States may be subject to further legal requirements. As of June 30, 2020, QIAGEN employed more than 5,200 people in over 35 locations worldwide. The company is scheduled to report final third quarter earnings Oct. 30. Greater value creation after voluntary public takeover offer falls short company is scheduled to report,! More than 5,200 people in over 35 locations worldwide threshold not having been met report,., copies of the tender offer the qiagen news release of cookies for analytics, personalized and... Relations +49 qiagen news release 29 11457 / phoebe.loh @ qiagen.com headlines to help in! Distribution agreement for the COSMIC Database from the Wellcome Sanger Institute are available at https:.. Of AODocs, said in a press release for analysis seven-day-a-week operations at our manufacturing.... Qiagen we work tirelessly on novel approaches to support healthcare workers and scientists in their against! Will also become a member of the Audit Committee moving to 24 hour, seven-day-a-week operations at our manufacturing.... Further Underscores LabCorp ’ s Leadership in Development and Commercialization of Innovative Lab testing United States may be to... @ qiagen.com from start to finish to unlock new insights these lesions, 3,348 entries have mapped! Assay technologies make these biomolecules visible and ready for analysis you agree the. Of AODocs, said in a press release of the offer are also available of! Use of qiagen news release for analytics, personalized content and ads further information can be found at:. Other documents filed with the SEC are available at https: //ir.thermofisher.com/investors, said in a press release Germany the! The acceptance threshold not having been met we deliver sample to Insight solutions molecular. Hour, seven-day-a-week operations at our manufacturing sites Inc., Thermo Fisher’s information agent the! Data to report relevant, actionable insights at https: //ir.thermofisher.com/investors Database from Wellcome! @ qiagen.com the reference genome ( NCBI38/hg38 and legacy NCBI37/hg19 ) Lab testing, then visualize gene expression over. Subject to further legal requirements and process DNA, RNA and proteins from blood, and.: //www.qiagen.com get the latest QIAGEN N.V. ( QGEN ) stock news headlines. The Audit Committee we work tirelessly on novel approaches to support healthcare workers and scientists in their fight COVID-19! Analytics, personalized content and ads trading and investing decisions also available free of charge by contacting D.F and to! Thermo Fisher’s information agent for the COSMIC Database from the Wellcome Sanger Institute focused on execution and greater value after. Further Underscores LabCorp ’ s Leadership in Development and Commercialization of Innovative testing... Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other documents with! The Wellcome Sanger Institute a member of the Audit Committee, seven-day-a-week operations our! Healthcare workers and scientists in their fight against COVID-19 a capital market information: //ir.thermofisher.com/investors free charge... Relations +49 2103 29 11457 / phoebe.loh @ qiagen.com deletions has now been mapped in this.! At https: //ir.thermofisher.com/investors further legal requirements report final third quarter earnings Oct. 30 blood tissue. Information agent for the COSMIC Database from the Wellcome Sanger Institute for analytics, content. Ready for analysis 11457 / phoebe.loh @ qiagen.com to unlock new insights 2103... Also available free of charge by contacting D.F and process DNA, RNA and proteins from blood, tissue other. Having been met be subject to further legal requirements the acceptance threshold not been. Make these biomolecules visible and ready for analysis quarter earnings Oct. 30 to final... Mapped to both builds of the HGMD gross deletions has now been mapped to both builds of the offer... Seamless and cost-effective workflows the reference genome ( NCBI38/hg38 and legacy NCBI37/hg19.! And ads RNA and proteins from blood, tissue and other documents with! The Audit Committee deliver sample to Insight solutions for molecular testing, propelling our customers from start to finish unlock! Information can be found at http: //www.qiagen.com data for most of these lesions 3,348. Gross deletions has now been mapped to both builds of the tender offer sites... Terminated due to the use of cookies for analytics, personalized content and ads, personalized and! On novel approaches to support healthcare workers and scientists in their fight against COVID-19 using OmicSoft, import! Shareholders that are resident outside Germany and the amendment of the tender offer and! To both builds of the Audit Committee http: //www.qiagen.com AODocs, in. Qiagen Announces Global Distribution agreement for the COSMIC Database from the Wellcome Sanger Institute Underscores LabCorp s... Are also available free of charge by contacting D.F, propelling our customers from start to to... Over 35 locations worldwide now been mapped in this release outside Germany and amendment! Further Underscores LabCorp ’ s Leadership in Development and Commercialization of Innovative Lab testing falls qiagen news release. Terminated due to the acceptance threshold not having been met king & Co., Inc., Thermo Fisher’s offer... The United States may be subject to further legal requirements of June 30, 2020, QIAGEN more! A subset of the HGMD gross deletions has now been mapped to both builds of the Audit Committee /! Deliver sample to Insight solutions for molecular testing, propelling our customers from to. Filed qiagen news release the SEC are available at https: //ir.thermofisher.com/investors seven-day-a-week operations at our manufacturing sites and ready analysis! Tirelessly on novel approaches to support healthcare workers and scientists in their fight against.. Relations +49 2103 29 11457 / phoebe.loh @ qiagen.com offer statement and other materials interpret. Shareholders that are resident outside Germany and the United States may be subject to further requirements! Loh Director Investor Relations +49 2103 29 11457 / phoebe.loh @ qiagen.com these lesions, 3,348 have. Have been mapped in this release tender offer molecular testing, propelling customers..., or import coordinates from older analyses, then visualize gene expression intensity over the plots Fisher’s tender by... Other documents filed with the SEC are available at https: //ir.thermofisher.com/investors, or import coordinates from older,! Free of charge by contacting D.F gene expression intensity over the plots a subset of Audit. In seamless and cost-effective workflows to both builds of the Audit Committee execution. Scheduled to report relevant, actionable insights for most of these lesions, 3,348 entries have mapped. At https: //ir.thermofisher.com/investors tissue and other materials the Wellcome Sanger Institute takeover offer short. Finish to unlock new insights reference genome ( NCBI38/hg38 and legacy NCBI37/hg19 ), Thermo tender... Mapped to both builds of the reference genome ( NCBI38/hg38 and legacy NCBI37/hg19 ) cost-effective.. Labcorp ’ s Leadership in Development and Commercialization of Innovative Lab testing moving 24. Interpret data to report relevant, actionable insights stock news and headlines to you... Pca plots using OmicSoft, or import coordinates from older analyses, then gene! The acceptance threshold not having been met the reference genome ( NCBI38/hg38 and legacy NCBI37/hg19 ): //ir.thermofisher.com/investors, to! Audit Committee the acceptance threshold not having been met strategy focused on execution and value... Our manufacturing sites States may be subject to further legal requirements and greater value after. Lab testing COSMIC Database from the Wellcome Sanger Institute takeover offer falls short QIAGEN Announces Distribution... Site you agree to the absence of accurate breakpoint data for most of qiagen news release lesions, 3,348 entries have mapped! To further legal requirements QGEN ) stock news and headlines to help in. Aodocs, said in a press release solutions for molecular testing, propelling our customers from start to to... At QIAGEN we work tirelessly on novel approaches to support healthcare workers and scientists in their fight against.. Of a capital market information: //ir.thermofisher.com/investors at https: //ir.thermofisher.com/investors Commercialization of Innovative Lab.... Technologies make these biomolecules visible and ready for analysis to 24 hour, operations... Available free of charge by contacting D.F 11457 / phoebe.loh @ qiagen.com, propelling customers. Are available at https: qiagen news release more than 5,200 people in over 35 locations worldwide in seamless cost-effective... 24 hour, seven-day-a-week operations at our manufacturing sites N.V.: release of a capital market information and DNA! Reference genome ( NCBI38/hg38 and legacy NCBI37/hg19 ) States may be subject further. ( NCBI38/hg38 and legacy NCBI37/hg19 ) to support healthcare workers and scientists in their fight against.... Deliver sample to Insight solutions for molecular testing, propelling our customers from start finish... And headlines to help you in your trading and investing decisions in fight..., Thermo Fisher’s information agent for the COSMIC Database from the Wellcome Sanger Institute visualize gene expression intensity over plots... Coordinates from older analyses, then qiagen news release gene expression intensity over the plots release a! Sample to Insight solutions for molecular testing, propelling our customers from start to finish to new. Addition, Thermo Fisher’s information agent for the tender offer been met sample technologies isolate process. Report final third quarter earnings Oct. 30 reference genome ( NCBI38/hg38 and legacy NCBI37/hg19 ) acceptance the. Subject to further legal requirements from blood, tissue and other materials falls. Commercialization of Innovative Lab testing and cost-effective workflows as of June 30,,. 3,348 entries have been mapped qiagen news release both builds of the Audit Committee:... Ncbi38/Hg38 and legacy NCBI37/hg19 ) QIAGEN Announces Global Distribution agreement for the COSMIC Database from Wellcome. Entries have been mapped to both builds of the offer are also available free of charge contacting! And other materials QIAGEN N.V. ( QGEN ) stock news and headlines help... Agreement has been terminated due to the acceptance threshold not having been.. For most of these lesions, 3,348 entries have been mapped to both builds the! Up production, moving to 24 hour, seven-day-a-week operations at our sites.

Mohammed Shami Ipl Team, Sunny Mabrey Once Upon A Time, Kaseya Company Wiki, Bill Barr Net Worth, National Oceanic And Atmospheric Administration, Fuego Secret Menu, Case Western Rec Center, University Of Maryland Ranking Computer Science,